AstraZeneca shares fall after Wainua trial miss leaves door open for rivals
AstraZeneca stock fell Thursday after its Wainua drug, co-developed with Ionis Pharmaceuticals, did not meet the main goal in a late-stage study for a rare heart disease. The setback deals a blow to one of AstraZeneca’s high-profile programs outside cancer. AstraZeneca is looking for new drugs to push revenue to $80 billion by 2030, up from $45.8 billion last year. The company aims to launch 20 new medicines by the end of the decade. The timing isn’t great.